{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:26:31Z","timestamp":1793262391312,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"crossref","award":["NET- 2011-02346784"],"award-info":[{"award-number":["NET- 2011-02346784"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Preclinical and pathology evidence suggests an involvement of brain dopamine (DA) circuitry in Alzheimer\u2019s disease (AD). We in vivo investigated if, when, and in which target regions [123I]FP-CIT-SPECT regional binding and molecular connectivity are damaged along the AD course.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively selected 16 amyloid-positive subjects with mild cognitive impairment due to AD (AD-MCI), 22 amyloid-positive patients with probable AD dementia (AD-D), and 74 healthy controls, all with available [123I]FP-CIT-SPECT imaging. We tested whether nigrostriatal vs. mesocorticolimbic dopaminergic targets present binding potential loss, via MANCOVA, and alterations in molecular connectivity, via partial correlation analysis. Results were deemed significant at <jats:italic>p<\/jats:italic> &lt; 0.05, after Bonferroni correction for multiple comparisons.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found significant reductions of [123I]FP-CIT binding in both AD-MCI and AD-D compared to controls. Binding reductions were prominent in the major targets of the ventrotegmental-mesocorticolimbic pathway, namely the ventral striatum and the hippocampus, in both clinical groups, and in the cingulate gyrus, in patients with dementia only. Within the nigrostriatal projections, only the dorsal caudate nucleus showed reduced [123I]FP-CIT binding, in both groups. Molecular connectivity assessment revealed a widespread loss of inter-connections among subcortical and cortical targets of the mesocorticolimbic network only (poor overlap with the control group as expressed by a Dice coefficient \u2264 0.25) and no alterations of the nigrostriatal network (high overlap with controls, Dice coefficient = 1).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Local- and system-level alterations of the mesocorticolimbic dopaminergic circuitry characterize AD, already in prodromal disease phases. These results might foster new therapeutic strategies for AD. The clinical correlates of these findings deserve to be carefully considered within the emergence of both neuropsychiatric symptoms and cognitive deficits.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-021-00925-1","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T11:03:08Z","timestamp":1636714988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer\u2019s disease phases"],"prefix":"10.1186","volume":"13","author":[{"given":"Arianna","family":"Sala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Paola","family":"Caminiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Presotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Chiaravalloti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"D\u2019Amelio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Paghera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Schillaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9784-292X","authenticated-orcid":false,"given":"Daniela","family":"Perani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"925_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/0006-8993(78)90562-0","volume":"159","author":"TD Reisine","year":"1978","unstructured":"Reisine TD, Yamamura HI, Bird ED, Spokes E, Enna SJ. Pre- and postsynaptic neurochemical alterations in Alzheimer\u2019s disease. Brain Res. 1978;159:477\u201381.","journal-title":"Brain Res."},{"key":"925_CR2","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.870120609","volume":"12","author":"JN Joyce","year":"1997","unstructured":"Joyce JN, Smutzer G, Whitty CJ, Myers A, Bannon MJ. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson\u2019s, Alzheimer\u2019s with parkinsonism, and Alzheimer\u2019s disease. Mov Disord. Wiley Online Library. 1997;12:885\u201397.","journal-title":"Mov Disord"},{"key":"925_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jnnp.52.2.193","volume":"52","author":"WR Gibb","year":"1989","unstructured":"Gibb WR, Mountjoy CQ, Mann DM, Lees AJ. The substantia nigra and ventral tegmental area in Alzheimer\u2019s disease and Down\u2019s syndrome. J Neurol Neurosurg Psychiatry. BMJ Publishing Group Ltd. 1989;52:193\u2013200.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"925_CR4","first-page":"199","volume":"3","author":"DMA Mann","year":"1984","unstructured":"Mann DMA, Yates PO, Marcyniuk B. Monoaminergic neurotransmitter systems in presenile Alzheimer\u2019s disease and in senile dementia of Alzheimer type. Clin Neuropathol. 1984;3:199\u2013205.","journal-title":"Clin Neuropathol."},{"issue":"219","key":"925_CR5","first-page":"230","volume":"73","author":"JO Rinne","year":"1986","unstructured":"Rinne JO, S\u00c4k\u00f6 E, Palj\u00c4rvi L, M\u00f6ls\u00c4 PK, Rinne UK. Brain dopamine D-1 receptors in senile dementia. J Neurol Sci. Springer. 1986;73(219):230.","journal-title":"J Neurol Sci"},{"key":"925_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00401-006-0146-9","volume":"113","author":"J Attems","year":"2007","unstructured":"Attems J, Quass M, Jellinger KA. Tau and \u03b1-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol. 2007;113:53\u201362.","journal-title":"Acta Neuropathol."},{"key":"925_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0197-4580(83)90002-7","volume":"4","author":"CG Gottfries","year":"1983","unstructured":"Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernas SA, Nordberg A, et al. Biochemical changes in dementia disorders of Alzheimer type (AD\/SDAT). Neurobiol Aging. 1983;4:261\u201371.","journal-title":"Neurobiol Aging."},{"key":"925_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1471-4159.1984.tb00913.x","volume":"43","author":"H Aral","year":"1984","unstructured":"Aral H, Kosaka K, Iizuka R. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem. 1984;43:388\u201393.","journal-title":"J Neurochem."},{"key":"925_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0022-510X(83)90149-1","volume":"60","author":"AJ Cross","year":"1983","unstructured":"Cross AJ, Crow TJ, Johnson JA, Joseph MH, Perry EK, Perry RH, et al. Monoamine metabolism in senile dementia of Alzheimer type. J Neurol Sci. 1983;60:383\u201392.","journal-title":"J Neurol Sci."},{"key":"925_CR10","first-page":"300","volume":"37","author":"AM Murray","year":"1995","unstructured":"Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN. Damage to dopamine systems differs between Parkinson\u2019s disease and Alzheimer\u2019s disease with parkinsonism. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. Wiley Online Library. 1995;37:300\u201312.","journal-title":"Ann Neurol Off J Am Neurol Assoc Child Neurol Soc"},{"key":"925_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0304-3940(95)12256-7","volume":"203","author":"D Storga","year":"1996","unstructured":"Storga D, Vrecko K, Birkmayer JGD, Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett. Elsevier. 1996;203:29\u201332.","journal-title":"Neurosci Lett"},{"key":"925_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archneur.58.3.466","volume":"58","author":"RA Sweet","year":"2001","unstructured":"Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Henteleff R, Pollock BG, et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol. 2001;58:466\u201372.","journal-title":"Arch Neurol."},{"key":"925_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0893-133X(87)90004-2","volume":"1","author":"P Seeman","year":"1987","unstructured":"Seeman P, Bzowej N, Guan H, Bergeron C, Reynolds G, Bird E, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s diseases. Neuropsychopharmacology. 1987;1:5\u201315.","journal-title":"Neuropsychopharmacology."},{"key":"925_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.brainres.2006.10.049","volume":"1131","author":"U Kumar","year":"2007","unstructured":"Kumar U, Patel SC. Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer\u2019s disease brain. Brain Res. 2007;1131:187\u201396.","journal-title":"Brain Res."},{"key":"925_CR15","doi-asserted-by":"publisher","unstructured":"Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Markakis D. Striatal dopamine receptors in Alzheimer-type dementia. Neurosci Lett. 1984;52(1\u20132):1\u20136. https:\/\/doi.org\/10.1016\/0304-3940(84)90341-052(1-2):1-6.","DOI":"10.1016\/0304-3940(84)90341-052(1-2):1-6"},{"key":"925_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF01249611","volume":"65","author":"JO Rinne","year":"1986","unstructured":"Rinne JO, S\u00c4k\u00f6 E, Palj\u00c4rvi L, M\u00f6ls\u00c4 PK, Rinne UK. Brain dopamine D-2 receptors in senile dementia. J Neural Transm. 1986;65:51\u201362.","journal-title":"J Neural Transm."},{"key":"925_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/0006-8993(88)90212-0","volume":"475","author":"R Cort\u00e9s","year":"1988","unstructured":"Cort\u00e9s R, Probst A, Palacios JM. Decreased densities of dopamine D1 receptors in the putamen and hippocampus in senile dementia of the Alzheimer type. Brain Res. 1988;475:164\u20137.","journal-title":"Brain Res."},{"key":"925_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0304-3940(93)90199-U","volume":"154","author":"JN Joyce","year":"1993","unstructured":"Joyce JN, Kaeger C, Ryoo H, Goldsmith S. Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer\u2019s disease. Neurosci Lett. 1993;154:171\u20134.","journal-title":"Neurosci Lett."},{"key":"925_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1212\/WNL.50.1.152","volume":"50","author":"JO Rinne","year":"1998","unstructured":"Rinne JO, Sahlberg N, Ruottinen H, N\u00e5gren K, Lehikoinen P. Striatal uptake of the dopamine reuptake ligand [11C]\u03b2-CFT is reduced in Alzheimer\u2019s disease assessed by positron emission tomography. Neurology. 1998;50:152\u20136.","journal-title":"Neurology."},{"key":"925_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1212\/WNL.47.4.1065","volume":"47","author":"G Pizzolato","year":"1996","unstructured":"Pizzolato G, Chierichetti F, Fabbri M, Cagnin A, Dam M, Ferlin G, et al. Reduced striatal dopamine receptors in Alzheimer\u2019s disease: single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology. 1996;47:1065\u20138.","journal-title":"Neurology."},{"key":"925_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/01.wnl.0000341932.21961.f3","volume":"72","author":"S Reeves","year":"2009","unstructured":"Reeves S, Brown R, Howard R, Grasby P. Increased striatal dopamine (D2\/D3) receptor availability and delusions in Alzheimer disease. Neurology. 2009;72:528\u201334.","journal-title":"Neurology."},{"key":"925_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1468-1331.1997.tb00338.x","volume":"4","author":"K Meguro","year":"1997","unstructured":"Meguro K, Itoh M, Yanai K, Takase K, Yamaguchi S, Ido T, et al. Psychiatric wandering behaviour in dementia patients correlated with increased striatal dopamine D2 receptor as shown by [11C]YM-09151-2 and positron emission tomography. Eur J Neurol. 1997;4:221\u20136.","journal-title":"Eur J Neurol."},{"key":"925_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1212\/WNL.55.2.205","volume":"55","author":"N Kemppainen","year":"2000","unstructured":"Kemppainen N, Ruottinen H, N\u00e5gren K, Rinne JO. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology. 2000;55:205\u20139.","journal-title":"Neurology."},{"key":"925_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1460-9568.2003.02716.x","volume":"18","author":"N Kemppainen","year":"2003","unstructured":"Kemppainen N, Laine M, Laakso MP, Kaasinen V, N\u00e5gren K, Vahlberg T, et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer\u2019s disease. Eur J Neurosci. 2003;18:149\u201354.","journal-title":"Eur J Neurosci."},{"key":"925_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3389\/fnins.2019.00617","volume":"13","author":"A Sala","year":"2019","unstructured":"Sala A, Perani D. Brain molecular connectivity in neurodegenerative diseases: recent advances and new perspectives using positron emission tomography. Front Neurosci. 2019;13:617.","journal-title":"Front Neurosci."},{"key":"925_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. Elsevier Ltd. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"925_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement."},{"key":"925_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00259-009-1267-x","volume":"37","author":"J Darcourt","year":"2010","unstructured":"Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu \u00d6L, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123 I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. Springer. 2010;37:443\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"925_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. Elsevier Inc. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"925_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11307-015-0889-6","volume":"18","author":"N Nicastro","year":"2016","unstructured":"Nicastro N, Garibotto V, Poncet A, Badoud S, Burkhard PR. Establishing on-site reference values for 123 I-FP-CIT SPECT (DaTscan\u00ae) using a cohort of individuals with non-degenerative conditions. Mol imaging Biol. Springer. 2016;18:302\u201312.","journal-title":"Mol imaging Biol"},{"key":"925_CR31","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s00259-019-04324-5","volume":"46","author":"A Pilotto","year":"2019","unstructured":"Pilotto A, Di Cola FS, Premi E, Grasso R, Turrone R, Gipponi S, et al. Extrastriatal dopaminergic and serotonergic pathways in Parkinson\u2019s disease and in dementia with Lewy bodies: a 123 I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. Springer. 2019;46:1642\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"925_CR32","first-page":"23","volume":"9","author":"FJG G\u00f3mez","year":"2018","unstructured":"G\u00f3mez FJG, Huertas I, Ram\u00edrez JAL, Sol\u00eds DG. Elaboraci\u00f3n de una plantilla de SPM para la normalizaci\u00f3n de im\u00e1genes de PET con 18F-DOPA. Imagen Diagn\u00f3stica. 2018;9:23\u20135.","journal-title":"Imagen Diagn\u00f3stica."},{"key":"925_CR33","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3233\/JAD-190954","volume":"75","author":"L Iaccarino","year":"2020","unstructured":"Iaccarino L, Sala A, Caminiti SP, Presotto L, Perani D. In vivo MRI structural and PET metabolic connectivity study of dopamine pathways in Alzheimer\u2019s disease. J Alzheimers Dis. 2020;75:1003\u201316.","journal-title":"J Alzheimers Dis."},{"key":"925_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1","volume":"439","author":"BJ Ciliax","year":"1999","unstructured":"Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol. 1999;439:38\u201356.","journal-title":"J Comp Neurol."},{"key":"925_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068910","volume":"8","author":"M Xia","year":"2013","unstructured":"Xia M, Wang J, He Y. BrainNet Viewer: a network visualization tool for human brain connectomics. PLoS One. 2013;8:e68910.","journal-title":"PLoS One."},{"key":"925_CR36","doi-asserted-by":"publisher","first-page":"14727","DOI":"10.1038\/ncomms14727","volume":"8","author":"A Nobili","year":"2017","unstructured":"Nobili A, Latagliata EC, Viscomi MT, Cavallucci V, Cutuli D, Giacovazzo G, et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer\u2019s disease. Nat Commun. 2017;8:14727.","journal-title":"Nat Commun."},{"key":"925_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.nbd.2018.05.006","volume":"116","author":"A Cordella","year":"2018","unstructured":"Cordella A, Krashia P, Nobili A, Pignataro A, La Barbera L, Viscomi MT, et al. Dopamine loss alters the hippocampus-nucleus accumbens synaptic transmission in the Tg2576 mouse model of Alzheimer\u2019s disease. Neurobiol Dis. Elsevier. 2018;116:142\u201354.","journal-title":"Neurobiol Dis"},{"key":"925_CR38","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/archneur.1990.00530120062011","volume":"47","author":"PJ Tyrrell","year":"1990","unstructured":"Tyrrell PJ, Sawle GV, Ibanez V, Bloomfield PM, Leenders KL, Frackowiak RS, et al. Clinical and positron emission tomographic studies in the \u2018extrapyramidal syndrome\u2019 of dementia of the Alzheimer type. Arch Neurol. 1990;47:1318\u201323.","journal-title":"Arch Neurol."},{"key":"925_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-171018","volume":"63","author":"M De Marco","year":"2018","unstructured":"De Marco M, Venneri A. Volume and connectivity of the ventral tegmental area are linked to neurocognitive signatures of Alzheimer\u2019s disease in humans. J Alzheimers Dis. 2018;63:1\u201314.","journal-title":"J Alzheimers Dis"},{"key":"925_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neurobiolaging.2018.08.012","volume":"72","author":"L Serra","year":"2018","unstructured":"Serra L, D\u2019Amelio M, Di Domenico C, Dipasquale O, Marra C, Mercuri NB, et al. In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer\u2019s disease. Neurobiol Aging. Elsevier Inc. 2018;72:72\u201382.","journal-title":"Neurobiol Aging"},{"key":"925_CR41","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1192\/bjp.136.6.533","volume":"136","author":"DMA Mann","year":"1980","unstructured":"Mann DMA, Lincoln J, Yates PO, Stamp JE, Toper S. Changes in the monoamine containing neurones of the human CNS in senile dementia. Br J Psychiatry. 1980;136:533\u201341.","journal-title":"Br J Psychiatry."},{"key":"925_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/npp.2009.129","volume":"35","author":"SN Haber","year":"2010","unstructured":"Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. Nature Publishing Group. 2010;35:4\u201326.","journal-title":"Neuropsychopharmacology"},{"key":"925_CR43","first-page":"333","volume":"11","author":"EA Wise","year":"2019","unstructured":"Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos JM. Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer\u2019s Coordinating Centers volunteers. Alzheimers Dement Diagn Assess Dis Monit. 2019;11:333\u20139.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit."},{"key":"925_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2410","volume-title":"Neuropsychiatric symptoms in Alzheimer\u2019s disease","author":"CG Lyketsos","year":"2011","unstructured":"Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer\u2019s disease: Elsevier; 2011."},{"key":"925_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0361-9230(82)90145-9","volume":"9","author":"LW Swanson","year":"1982","unstructured":"Swanson LW. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull. 1982;9:321\u201353.","journal-title":"Brain Res Bull."},{"key":"925_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.nbd.2018.05.021","volume":"117","author":"CT Tiernan","year":"2018","unstructured":"Tiernan CT, Ginsberg SD, He B, Ward SM, Guillozet-Bongaarts AL, Kanaan NM, et al. Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer\u2019s disease. Neurobiol Dis. 2018;117:125\u201336.","journal-title":"Neurobiol Dis."},{"key":"925_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neurobiolaging.2019.09.014","volume":"85","author":"OK Hassani","year":"2020","unstructured":"Hassani OK, Rymar VV, Nguyen KQ, Huo L, Cloutier JF, Miller FD, et al. The noradrenergic system is necessary for survival of vulnerable midbrain dopaminergic neurons: implications for development and Parkinson\u2019s disease. Neurobiol Aging. 2020;85:22\u201337.","journal-title":"Neurobiol Aging."},{"key":"925_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40478-017-0411-2","volume":"5","author":"SC Kelly","year":"2017","unstructured":"Kelly SC, He B, Perez SE, Ginsberg SD, Mufson EJ, Counts SE. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer\u2019s disease. Acta Neuropathol Commun. 2017;5:8.","journal-title":"Acta Neuropathol Commun."},{"key":"925_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nature19325","volume":"537","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Duszkiewicz AJ, Sonneborn A, Spooner PA, Yamasaki M, Watanabe M, et al. Locus coeruleus and dopaminergic consolidation of everyday memory. Nature. Nature Publishing Group. 2016;537:357\u201362.","journal-title":"Nature"},{"key":"925_CR50","first-page":"1129","volume":"37","author":"A Abi-Dargham","year":"1996","unstructured":"Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. Society of Nuclear Medicine. 1996;37:1129.","journal-title":"J Nucl Med"},{"key":"925_CR51","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/(SICI)1098-2396(199704)25:4<345::AID-SYN5>3.0.CO;2-A","volume":"25","author":"U Scheffel","year":"1997","unstructured":"Scheffel U, Lever JR, Abraham P, Parham KR, Mathews WB, Kopajtic T, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse. Wiley Online Library. 1997;25:345\u20139.","journal-title":"Synapse"},{"key":"925_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/jnnp.62.2.133","volume":"62","author":"J Booij","year":"1997","unstructured":"Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I] FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. BMJ Publishing Group Ltd. 1997;62:133\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"925_CR53","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.neuroimage.2005.03.034","volume":"26","author":"G Andringa","year":"2005","unstructured":"Andringa G, Drukarch B, Bol JGJM, de Bruin K, Sorman K, Habraken JBA, et al. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson\u2019s disease. Neuroimage. Elsevier. 2005;26:1150\u20138.","journal-title":"Neuroimage"},{"key":"925_CR54","doi-asserted-by":"publisher","unstructured":"Koch W, Unterrainer M, Xiong G, Bartenstein P, Diemling M, Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, Kapucu OL, Kluge A, Ziebell M, Darcourt J, Nobili F, Pagani M, Hesse S, Vander Borght T, Van Laere K, Tatsch K, la Foug\u00e8re C. Extrastriatal binding of [\u00b9\u00b2\u00b3I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging. 2014;41(10):1938\u201346. https:\/\/doi.org\/10.1007\/s00259-014-2785-8.","DOI":"10.1007\/s00259-014-2785-8"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00925-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00925-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00925-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T12:03:54Z","timestamp":1650283434000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00925-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00925-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"assertion":[{"value":"5 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from each subject or relatives; the protocols conformed to the ethical standards of the Declaration of Helsinki for the protection of human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}